What happened with DYN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Dyne Therapeutics is developing treatments for patients with rare genetic muscle diseases. Its FORCE platform attaches a drug payload to an antibody fragment designed to carry it into muscle tissue. Its clinical programs include z-rostudirsen for Duchenne muscular dystrophy and z-basivarsen for myotonic dystrophy type 1. All its candidates remain in clinical or preclinical development, and the platform’s approach is unproven.
Dyne currently funds its work mainly by selling shares and borrowing under the Hercules Loan Agreement, rather than selling medicines. Future product sales depend first on completing trials and obtaining regulatory approval. After approval, physician and patient acceptance would matter, and most patients would need insurance or other third-party coverage to afford treatment.
Dyne also depends on outside manufacturers and a small number of suppliers for the components of its medicines. It has no manufacturing facilities of its own, so advancing its programs and eventually supplying approved products relies on those firms meeting quality and regulatory requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Sarepta competes with Dyne's developing Duchenne muscular dystrophy (DMD) treatment by selling medicines that skip parts of the gene's instructions and the gene therapy ELEVIDYS. Watch ELEVIDYS safety and U.S. patient eligibility: in November 2025, Sarepta announced a boxed liver-injury warning and removed non-ambulatory patients from its indication.
Entrada challenges both of Dyne's lead programs with DMD exon-skipping candidates and VX-670 for myotonic dystrophy type 1 (DM1). Vertex pays for Entrada's continued preclinical work on VX-670 and handles its global development outside that collaboration work, making VX-670's clinical progress the DM1 news to watch.
PepGen competes with Dyne in DM1 by attaching short peptides to RNA-targeting medicines to help them enter muscle cells, rather than using Dyne's antibody-linked approach. Watch whether its DM1 candidates deliver medicine into muscle safely; PepGen reported no revenue in 2025.
Novartis competes with Dyne across DM1, DMD and facioscapulohumeral muscular dystrophy (FSHD) through its ownership of Avidity, which develops antibody-linked RNA medicines. For Dyne holders, Avidity's muscle-disease clinical progress is more directly relevant than Novartis's broader prescription-drug sales.
Wave Life Sciences and Dyne are developing competing DMD medicines that skip selected parts of RNA instructions, using different oligonucleotide technologies. Watch Wave's DMD treatment results rather than its collaboration revenue, which came entirely from GSK in 2025.
Solid Biosciences' SGT-003 gene therapy seeks to treat the same DMD patients' disease as Dyne's RNA-targeting program, but through a different approach. SGT-003's clinical and regulatory progress is the relevant competitive signal; it remains an investigational treatment, not a marketed product.
Arrowhead competes with Dyne in DM1 and FSHD through muscle-targeted RNA programs licensed to Sarepta. Watch those programs' development: they use cells' own machinery to break down selected RNA messages and reduce protein production, a process called RNA interference.
REGENXBIO's RGX-202 gene therapy competes with Dyne's approach to restoring dystrophin in DMD. RGX-202's clinical and regulatory progress is the development to watch, rather than the payments REGENXBIO receives for licensing its gene-delivery technology to other drugmakers.
PTC Therapeutics already earns revenue from the DMD medicines Translarna and Emflaza and names Dyne's developing treatment as potential competition. Changes in access to those DMD medicines are the relevant news for Dyne, rather than PTC's other rare-disease drug sales.
BioMarin's BMN 351 competes with Dyne's DMD program in skipping exon 51, a selected part of the gene's instructions. Watch BMN 351's clinical results rather than BioMarin's current drug sales, which come from treatments for other diseases.
BioMarin Pharmaceuticals Inc earningsBMRN
BioMarin's report may show how BMN 351 is progressing in clinical development, a competing exon 51-skipping approach aimed at the same DMD treatment area as Dyne's program.
Look for BioMarin's update on BMN 351: clinical progress, trial delays or other setbacks, then compare that with the development stage of Dyne's DMD program. If BMN 351 advances, a competing treatment for the same patient group is moving forward, and Dyne will need to show the value of its own approach. If the program stalls or encounters setbacks, near-term competitive pressure is lower, but that does not establish that Dyne's treatment works. The conclusion is about progress in a competing approach, not a direct comparison of the treatments' efficacy.
Fed Interest Rate Decision
Fed rate decisions change interest rates that can affect Dyne’s earnings on invested cash and the interest it pays on its floating-rate loan.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could increase income on Dyne’s invested cash, but also raise interest costs on its loan, reducing the funds available for research and development.
If it comes in below expectations
Lower rates could reduce income on Dyne’s invested cash, but also lower interest costs on its loan, leaving more funds available for research and development.
Dyne Therapeutics, Inc. earningsThis company
Dyne has no product-sales revenue yet, so this report will show whether the cash it spends advancing its DMD and DM1 programs leaves enough runway to keep developing them.
Read cash on hand alongside cash used in operations, and separate operating spending from cash raised through stock sales or loans. If cash remains ample relative to operating use while Dyne continues investing in its DMD and DM1 programs, its existing funds are better positioned to support development. If operating cash use accelerates and the balance shrinks, even financing inflows do not change the fact that operations are consuming cash faster, bringing funding pressure closer. The question is whether Dyne can keep advancing its clinical programs, not just how much cash appears on the balance sheet.
PepGen Inc. earningsPEPG
Any update in PepGen's report on its DM1 candidates will show whether its peptide-based delivery approach is advancing in the same disease area where it competes with Dyne's antibody-linked approach.
Look for whether PepGen reports progress in getting its DM1 candidates into muscle and whether it reports safety problems; compare that with Dyne's antibody-linked RNA-targeting approach. If PepGen reports progress on delivery and safety, a competing route is advancing, and Dyne still needs to show that its own approach works in patients. Delays or safety problems would reduce near-term competitive pressure, but would not prove Dyne's approach is more effective or safer. The test is which approach continues to advance through clinical study.
